MENU
岡山肺癌研究会 | OLCSG
  1. ホーム
  2. Publications

Publications

研究業績

論文発表

介入研究

研究No.論文タイトル/著者など
OLCSG1801Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.
Hosokawa S, Ichihara E, Harada D, Kuyama S, Inoue K, Gemba K, Ichikawa H, Kato Y, Oda N, Oze I, Tamura T, Kozuki T, Umeno T, Kubo T, Hotta K, Bessho A, Maeda Y, Kiura K.
Int J Clin Oncol. 2022 Jul;27(7):1139-1144. doi: 10.1007/s10147-022-02164-2. Epub 2022 May 10.
PMID: 35534642
OLCSG1401A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401.
Ninomiya K, Yokoyama T, Hotta K, Oze I, Katsui K, Hata T, Yoshioka H, Bessho A, Hosokawa S, Kuyama S, Kudo K, Kozuki T, Harada D, Yasugi M, Murakami T, Nakanishi M, Takigawa N, Maeda Y, Kiura K; Okayama Lung Cancer Study Group.
Support Care Cancer. 2021 Sep;29(9):5237-5244. doi: 10.1007/s00520-021-06092-1. Epub 2021 Mar 1.
PMID: 33649919
OLCSG1403A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.
Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1.
PMID: 30276451
OLCSG1404A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K.
Lung Cancer. 2018 Jan;115:103-108. doi: 10.1016/j.lungcan.2017.11.025. Epub 2017 Nov 28.
PMID: 29290249
OLCSG1405Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D, Isozaki H, Kozuki T, Yokoyama T, Yoshioka H, Bessho A, Hosokawa S, Takata I, Takigawa N, Hotta K, Kiura K; Okayama Lung Cancer Study Group.
Thorac Cancer. 2021 Mar;12(5):643-649. doi: 10.1111/1759-7714.13825. Epub 2021 Jan 20.
PMID: 33470536
OLCSG1406Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K.
Asia Pac J Clin Oncol. 2021 Feb;17(1):101-108. doi: 10.1111/ajco.13423. Epub 2020 Sep 3.
PMID: 32885583
OLCSG1303A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.
Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K.
Asia Pac J Clin Oncol. 2019 Aug;15(4):250-256. doi: 10.1111/ajco.13147. Epub 2019 Apr 1.
PMID: 30938103
OLCSG1201Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K.
Int J Clin Oncol. 2016 Feb;21(1):81-7. doi: 10.1007/s10147-015-0860-1. Epub 2015 Jun 21.
PMID: 26093520
OLCSG1202A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, Kubo T, Harada D, Fujimoto N, Nakanishi M, Umeno T, Okada T, Chikamori K, Yamagishi T, Ohashi K, Ichihara E, Takigawa N, Tanimoto M, Kiura K.
Lung Cancer. 2017 Oct;112:188-194. doi: 10.1016/j.lungcan.2017.08.010. Epub 2017 Aug 12.
PMID: 29191594
OLCSG1001Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.
J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434.
PMID: 25695221
OLCSG0801A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K.
Eur J Cancer. 2014 Nov;50(16):2783-90. doi: 10.1016/j.ejca.2014.07.024. Epub 2014 Aug 26.
PMID: 25172295
OLCSG0705A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M; Okayama Lung Cancer Study Group.
J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063.
PMID: 19898258
OLCSG0501A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K.
Lung Cancer. 2015 Feb;87(2):141-7. doi: 10.1016/j.lungcan.2014.11.001. Epub 2014 Nov 8.
PMID: 25534129
OLCSG0502A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.
Takigawa N, Kiura K, Hotta K, Hosokawa S, Nogami N, Aoe K, Gemba K, Fujiwara K, Harita S, Takemoto M, Himei K, Shinkai T, Fujiwara Y, Takata S, Tabata M, Kanazawa S, Tanimoto M; Okayama Lung Cancer Study Group.
Lung Cancer. 2011 Jan;71(1):60-4. doi: 10.1016/j.lungcan.2010.04.012. Epub 2010 May 6.
PMID: 20451285
OLCSG0503A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y, Kiura K, Hotta K, Takigawa N, Tabata M, Matsuo K, Yoshioka H, Hayashi H, Kawai H, Aoe K, Maeda T, Ueoka H, Tanimoto M.
J Thorac Oncol. 2010 Sep;5(9):1430-4. doi: 10.1097/JTO.0b013e3181e3248e.
PMID: 20651615
OLCSG0401A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N, Hotta K, Kuyama S, Kiura K, Takigawa N, Chikamori K, Shibayama T, Kishino D, Hosokawa S, Tamaoki A, Harita S, Tabata M, Ueoka H, Shinkai T, Tanimoto M.
Lung Cancer. 2011 Oct;74(1):80-4. doi: 10.1016/j.lungcan.2011.01.018. Epub 2011 Feb 18.
PMID: 21334093
OLCSG0402Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N, Hotta K, Segawa Y, Takigawa N, Hosokawa S, Oze I, Fujii M, Ichihara E, Shibayama T, Tada A, Hamada N, Uno M, Tamaoki A, Kuyama S, Ikeda G, Osawa M, Takata S, Tabata M, Tanimoto M, Kiura K.
Acta Oncol. 2012 Jul;51(6):768-73. doi: 10.3109/0284186X.2011.648342. Epub 2012 Jan 27.
PMID: 22283472
OLCSG0102A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, Maeda T, Kozuki T, Fujimoto N, Ninomiya K, Takemoto M, Kanazawa S, Takigawa N, Tabata M, Tanimoto M, Ueoka H, Kiura K.
Cancer Chemother Pharmacol. 2016 Oct;78(4):769-74. doi: 10.1007/s00280-016-3135-2. Epub 2016 Aug 20.
PMID: 27544764
OLCSG0007Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M.
J Clin Oncol. 2010 Jul 10;28(20):3299-306. doi: 10.1200/JCO.2009.24.7577. Epub 2010 Jun 7.
PMID: 20530281

観察研究

研究No.著者/論文タイトルなど
OLCSG-ID/ICDMorita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, et al.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Int J Cancer. 2024 May;154(9):1607–15.
OLCSG-ID/ICDFrequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Taoka M, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato A, Oda N, Kano H, Nakamura K, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Oze I, Kiura K, Maeda Y, Hotta K.
Cancers (Basel). 2024 Dec 6;16(23):4089. doi: 10.3390/cancers16234089.
PMID: 39682275
OLCSG-ID/ICDThe Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study.
Nishimura T, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato K, Oda N, Kano H, Kishino D, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Hotta K, Maeda Y, Kiura K.
Cancers (Basel). 2022 Dec 14;14(24):6184. doi: 10.3390/cancers14246184.
PMID: 36551668
OLCSG-ID/ICDThe impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
Ichihara E, Harada D, Inoue K, Sato K, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
Lung Cancer. 2020 Jan;139:140-145. doi: 10.1016/j.lungcan.2019.11.011. Epub 2019 Nov 18.
PMID: 31786476
OLCSG-ID/ICDCharacteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10.
PMID: 32648165
OLCSG-ID/ICDUtility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
Kano H, Ichihara E, Harada D, Inoue K, Kayatani H, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Ninomiya K, Hotta K, Maeda Y, Kiura K.
Cancer Sci. 2020 Oct;111(10):3739-3746. doi: 10.1111/cas.14590. Epub 2020 Aug 26.
PMID: 32726470
OLCSG-ID/ICDImpact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
Hosokawa S, Ichihara E, Bessho A, Harada D, Inoue K, Shibayama T, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
Jpn J Clin Oncol. 2021 Feb 8;51(2):279-286. doi: 10.1093/jjco/hyaa180.
PMID: 33049757
OLCSG-ID/ICDSignificance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Hara N, Ichihara E, Harada D, Inoue K, Fujiwara K, Hosokawa S, Kishino D, Haruyuki K, Ochi N, Oda N, Hotta K, Maeda Y, Kiura K.
J Cancer Res Clin Oncol. 2021 Dec;147(12):3749-3755. doi: 10.1007/s00432-021-03615-5. Epub 2021 Mar 29.
PMID: 33779840
OLCSG-ID/ICDThe effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
Eur J Cancer. 2021 May;149:73-81. doi: 10.1016/j.ejca.2021.02.040. Epub 2021 Apr 7.
PMID: 33838391
OLCSG-ID/ICDMore than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.
Ando C, Ichihara E, Yokoyama T, Inoue K, Tamura T, Fujiwara K, Oda N, Kano H, Kishino D, Watanabe K, Inoue M, Ochi N, Onishi F, Ichikawa H, Kobe H, Tachibana S, Hotta K, Maeda Y, Kiura K.
J Cancer Res Clin Oncol. 2023 Jul;149(8):4933-4938. doi: 10.1007/s00432-022-04415-1. Epub 2022 Oct 29.
PMID: 36308525
OLCSG-ID/ICDEfficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer.
Kubo T, Ichihara E, Harada D, Inoue K, Fujiwara K, Hosokawa S, Kishino D, Kawai H, Ochi N, Oda N, Hara N, Hotta K, Tabata M, Maeda Y, Kiura K.
Respir Investig. 2023 Sep;61(5):643-650. doi: 10.1016/j.resinv.2023.06.005. Epub 2023 Jul 20.
PMID: 37480603
OLCSG2102Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, Inoue K, Chikamori K, Kudo K, Ochi N, Harada D, Maeda Y, Kiura K.
Thorac Cancer. 2022 Feb;13(3):453-459. doi: 10.1111/1759-7714.14281. Epub 2021 Dec 28.
PMID: 34964270
OLCSG2102　　Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.
Harada D, Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, Inoue K, Chikamori K, Kudo K, Ochi N, Maeda Y, Kiura K.
Thorac Cancer. 2023 Jan;14(3):231-236. doi: 10.1111/1759-7714.14737. Epub 2022 Nov 20.
PMID: 36404396

インターグループ研究

研究No.著者/論文タイトルなど
Afa-Bev-CS関連A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, Kanaji N, Yasugi M, Shibayama T, Aoe K, Ochi N, Fujitaka K, Kodani M, Ueda Y, Watanabe K, Bessho A, Sugimoto K, Oze I, Hotta K, Kiura K.
Lung Cancer. 2023 Oct;184:107349. doi: 10.1016/j.lungcan.2023.107349. Epub 2023 Aug 19.
PMID: 37651927
HER2-CS関連A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network.
Chest. 2019 Aug;156(2):357-366. doi: 10.1016/j.chest.2019.01.011. Epub 2019 May 6.
PMID: 31072612
HER2-CS関連Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.
Ohashi K, Ninomiya K, Yoshioka H, Bessho A, Shibayama T, Aoe K, Ishikawa N, Kozuki T, Kawai H, Kuyama S, Miyoshi S, Fujitaka K, Obata H, Tsubata Y, Awaya Y, Inoue M, Inoue K, Horita N, Yanai H, Hotta K, Kiura K.
Lung Cancer. 2020 Dec;150:83-89. doi: 10.1016/j.lungcan.2020.09.024. Epub 2020 Oct 1.
PMID: 33096420
HER2-CS関連Pilot evaluation of a HER2 testing in non-small-cell lung cancer.
Hotta K, Yanai H, Ohashi K, Ninomiya K, Nakashima H, Kayatani H, Takata M, Kiura K.
J Clin Pathol. 2020 Jun;73(6):353-357. doi: 10.1136/jclinpath-2019-206204. Epub 2019 Dec 3.
PMID: 31796633
HER2-CS関連A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K.
J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5.
PMID: 29313813
HER2-CS関連Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
Ohashi K, Hotta K, Hirata T, Aoe K, Kozuki T, Ninomiya K, Kayatani H, Yanai H, Toyooka S, Hinotsu S, Takata M, Kiura K.
Clin Lung Cancer. 2017 Jan;18(1):92-95. doi: 10.1016/j.cllc.2016.06.014. Epub 2016 Jul 9.
PMID: 27497829
OLCSG1402/
TORG1424		A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL).
Nogami N, Kubo T, Bessho A, Sakugawa M, Ikeo S, Yokoyama T, Seki N, Ochiai R, Fujimoto N, Murakami S, Kaira K, Harada T, Kishino D, Takiguchi Y, Shimokawa T, Kiura K, Yamashita N, Okamoto H.
Jpn J Clin Oncol. 2024 Jul 7;54(7):805-812. doi: 10.1093/jjco/hyae044.
PMID: 38594880
OLCSG0905/
LOGIK0902		Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Hotta K, Saeki S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Gemba K, Shiojiri M, Kato Y, Ninomiya T, Kubo T, Kishimoto J, Shioyama Y, Katsui K, Sasaki J, Kiura K, Sugio K.
ESMO Open. 2021 Aug;6(4):100191. doi: 10.1016/j.esmoop.2021.100191. Epub 2021 Jun 18.
PMID: 34153652
OLCSG0905/
LOGIK0902		Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Hotta K, Saeki S, Sakata S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Inoue K, Gemba K, Kubo T, Sato A, Ichihara E, Watanabe H, Kishimoto J, Shioyama Y, Katsui K, Sugio K, Kiura K.
Int J Clin Oncol. 2025 Mar;30(3):497-503. doi: 10.1007/s10147-025-02696-3. Epub 2025 Feb 5.
PMID: 39910007
OLCSG0905/
LOGIK0902		Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J, Tanimoto M, Kiura K, Ichinose Y.
Clin Lung Cancer. 2016 Jan;17(1):75-9. doi: 10.1016/j.cllc.2015.08.004. Epub 2015 Aug 18.
PMID: 26387039
OLCSG0905/
LOGIK0902		Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study.
Sho Saeki, Katsuyuki Hotta, Shinya Sakata, Naohiro Oda, Koji Inoue, Tomoki Tamura, Ryo Toyozawa, Daijiro Harada, Kentaro Tanaka, Koji Inoue, Yoshiyuki Shioyama, Kenichi Gemba, Tomonari Sasaki, Akihiro Bessho, Junji Kishimoto, Kuniaki Katsui, Katsuyuki Kiura, Kenji Sugio.
Cureus 2025 (in press).
PMID: 未